RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Clinical trials for RELAPSED/REFRACTORY B-CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human trial tests new pill for tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug called AC676 in adults with B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Accutar Biotechnology Inc • Aim: Disease control
Last updated Apr 02, 2026 00:56 UTC
-
New 'Living Drug' trial targets tough blood cancers
Disease control Recruiting nowThis study is testing the safety and effectiveness of a new type of CAR-T cell therapy for adults with B-cell blood cancers that have come back or stopped responding to other treatments. Doctors will collect and modify a patient's own immune cells to target a protein called BAFFR…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Apr 02, 2026 00:56 UTC
-
New hope for patients with aggressive blood cancers that Won't quit
Disease control Recruiting nowThis is an early-stage study testing a new CAR-T cell therapy called IASO208 for adults with aggressive B-cell blood cancers that have come back or not responded to standard treatments. The main goal is to find a safe dose and see how the body handles the treatment, while also ch…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First-in-Human trial tests novel 'Messenger' therapy for tough blood cancers
Disease control Recruiting nowThis is a very early study to test the safety and initial effects of a new experimental treatment called ZZSW-01 for adults with advanced B-cell blood cancers that have come back or not responded to standard therapies. The treatment involves giving patients modified immune cells …
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for patients Who've run out of options: experimental cancer drug enters human testing
Disease control Recruiting nowThis is the first study in people testing a new drug called UBX-303061 for patients with advanced B-cell cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also …
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Ubix Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC